Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

Trial Details

NCT ID

NCT06496789

Phase

PHASE2

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Status

RECRUITING

Cancer Type

Adenocarcinoma Esophageal Cancer

Interventions

• Serplulimab+SOX

Locations (sample)

• Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

• histologically documented adenocarcinoma of Gastric or Gastroesophageal Junction. 2. clinically diagnosed stage T3-4aN+M0 according to ultrasound e…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.